The analysis revealed that 81% of individuals treated with Livdelzi achieved a composite biochemical response.

At AHA 2024, the safety of GLP-1R agonists in heart failure and chronic kidney disease (CKD) patients was discussed.

In 2017, the CONSORT-CHM Formulas 2017 extension was introduced to enhance the reporting transparency of randomized ...

Before propensity matching, mothers of tetracycline-exposed infants were more often in the youngest and oldest age strata and ...

Mavorixafor was generally well tolerated as a monotherapy and in combination with G-CSF, with no drug-related serious adverse ...

The FDA recently approved a phase 2 clinical trial to investigate the efficacy of leronlimab in patients with relapsed or ...

In this analysis, Repare followed patients ... on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or ...

Similarly, TransCelerate’s Comparator Network (CN) Initiative, which aims to enhance patient safety by establishing a reliable mechanism to acquire clinical trial comparator and co-therapy drugs ...

Robert F. Kennedy Jr. vowed to purge the U.S. Food and Drug Administration shortly before being chosen as President-elect ...

Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...